CagriSema vs. tirzepatide: Amylin/GLP-1 vs. GIP/GLP-1

Molecular architecture and receptor pharmacology: two fundamentally different designs

CagriSema and Tirzepatide are not simply two versions of the same idea — they are built on different molecular foundations and activate entirely different receptor systems. CagriSema is a fixed-dose combination of two distinct peptides: cagrilintide 2.4 mg (a long-acting amylin analog) and semaglutide 2.4 mg (a GLP-1 receptor agonist). Each component retains independent receptor selectivity, meaning amylin receptors (AMY1, AMY2, AMY3 — heterodimers of the calcitonin receptor with receptor activity-modifying proteins) and GLP-1 receptors are activated through separate, non-competing pathways.

Tirzepatide takes a structurally different approach: it is a single unimolecular peptide engineered for dual receptor agonism, structurally based on the GIP sequence with modifications for balanced dual activity. It activates both GIP receptors (GIPR) and GLP-1 receptors simultaneously, with extended half-life achieved through fatty acid acylation. This architectural difference — combination of two independent peptides versus one engineered molecule — has downstream consequences for receptor distribution, signaling dynamics, and clinical behaviour.

The receptor localization difference is clinically significant. Amylin receptors concentrate in brainstem satiety centres — the area postrema and NTS — while GLP-1 receptors are found in the hypothalamic arcuate nucleus, paraventricular nucleus, and peripheral tissues including pancreatic β-cells and gastric smooth muscle. Because these distributions are complementary and non-overlapping, CagriSema’s two components can produce additive effects without direct receptor competition. Tirzepatide’s GIP receptors, meanwhile, are expressed in adipose tissue and bone in addition to the CNS, enabling metabolic effects not available to CagriSema’s amylin component.

How each therapy drives weight loss through distinct neurological and metabolic pathways

CagriSema achieves appetite suppression through brainstem-mediated satiety signalling — the amylin component acts on the area postrema and NTS, regions that process peripheral satiety signals and regulate meal termination. This is additive to semaglutide’s hypothalamic appetite suppression. A further mechanistic advantage is dual gastric emptying delay: amylin slows gastric emptying via brainstem-mediated pathways, while GLP-1 does so through vagal and direct smooth muscle mechanisms. Amylin also acts on both homeostatic and hedonic brain regions, potentially reducing reward-driven eating beyond simple caloric regulation.

Tirzepatide’s weight loss mechanisms are concentrated in different anatomical territories. The GIP component may enhance thermogenesis through brown adipose tissue (BAT), inducing a thermogenic-like amino acid signature with increased BCAA catabolism and TCA cycle intermediates in BAT. GIP may also augment GLP-1 effects through heterodimer formation (GLP-1R/GIPR) and complementary signalling cascades, and may exert central anorexic effects through hypothalamic and hippocampal GIP receptor expression.

“CagriSema-induced weight loss in diet-induced obese models relies on preserved mitochondrial leak respiration in skeletal muscle — approximately 15% lower calorie intake is required compared to weight-matched controls to achieve similar weight loss, indicating a maintained metabolic rate.”

The metabolic adaptation prevention mechanisms also diverge. CagriSema preserves mitochondrial leak respiration in skeletal muscle, maintaining energy expenditure despite significant weight reduction. Tirzepatide prevents metabolic adaptation through BAT activation — a thermogenic route rather than a skeletal muscle route. Both approaches counter the compensatory metabolic slowdown that typically accompanies weight loss, but through entirely distinct tissue targets, as documented in research published in peer-reviewed literature reviewed by NEJM and referenced by regulatory bodies including the FDA.

Clinical efficacy: weight loss and glycemic outcomes from REDEFINE, SURPASS, and SURMOUNT

Both therapies achieve comparable maximum weight loss of approximately 20–22%, but the route to that outcome — and the consistency across patient populations — differs meaningfully. In REDEFINE-1 (adults with obesity without T2DM), CagriSema achieved 20.4% mean weight loss at 68 weeks using the treatment policy estimand, and 22.7% using the trial product estimand. A further 34.7% of participants achieved ≥25% weight loss, and 19.3% achieved ≥30% weight loss. In the T2DM population (REDEFINE-2), mean weight loss was 15.7% at 68 weeks.

Tirzepatide achieved up to 22.5% mean weight loss in SURMOUNT-1 at 72 weeks (highest 15 mg dose). In the SURPASS T2DM trials, weight loss ranged from approximately 7.0 to 11.7 kg (roughly 5.4–11.7% reduction). Importantly, 82.5% of Tirzepatide patients reached the highest dose in obesity trials — a substantially better dose completion rate than CagriSema’s 57.3%.

On glycemic efficacy, Tirzepatide demonstrates a consistent edge in head-to-head comparisons with semaglutide monotherapy. SURPASS trials showed HbA1c reductions of 1.87–2.58% (dose-dependent), with 23.0–62.4% of patients achieving HbA1c below 5.7% (normoglycemia). CagriSema achieved 73.5% of T2DM patients reaching HbA1c ≤6.5% in REDEFINE-2, and 87.7% of prediabetic patients achieved normoglycemia — a clinically meaningful result for diabetes prevention. According to WHO criteria, both outcomes represent substantial glycemic benefit in populations at high metabolic risk.

Cardiometabolic benefits beyond weight and glucose: where the evidence currently stands

Tirzepatide currently holds a more extensive published cardiovascular evidence base. In HFpEF patients with obesity, Tirzepatide demonstrated a 38% risk reduction in heart failure outcomes — including hospitalization, death, and medication escalation. Triglyceride reductions of 19–24.8% were observed in SURPASS trials, compared to 11.5% with semaglutide. Inflammatory biomarkers including YKL-40, ICAM-1, leptin, and hsCRP were also reduced. The FDA has approved Tirzepatide (as Zepbound) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity — an indication that extends its cardiometabolic utility beyond glucose and weight.

CagriSema’s cardiovascular profile, while promising, awaits the definitive outcomes data that REDEFINE-3 will provide. What is established is that CagriSema significantly reduces blood pressure, lowers CRP (a marker of systemic inflammation), improves lipid profiles, and reduces the proportion of patients at risk of developing heart disease over time. The amylin component’s brainstem-mediated actions may offer cardiovascular benefits through pathways not yet fully characterised in clinical trials — an area of active investigation aligned with research priorities outlined by bodies including the European Society of Cardiology.

Both therapies share the GLP-1 receptor agonist class benefits well-documented in cardiovascular outcomes research: blood pressure reduction, anti-inflammatory effects, and lipid profile improvement. The incremental cardiovascular benefit from each therapy’s second receptor target — amylin for CagriSema, GIP for Tirzepatide — remains an area where long-term outcomes data will be decisive.

Safety, tolerability, and the dose escalation challenge

The most clinically consequential safety difference between CagriSema and Tirzepatide is gastrointestinal tolerability — and it has direct implications for efficacy, because patients who cannot reach target doses receive attenuated weight loss benefit. CagriSema’s nausea incidence is approximately 55%, compared to 30–40% (dose-dependent) for Tirzepatide. GI-related discontinuation rates are 6–8.4% for CagriSema versus 4–6% for Tirzepatide. The mechanistic explanation is straightforward: CagriSema produces dual gastric emptying delay through both amylin (brainstem-mediated) and GLP-1 (vagal/smooth muscle) pathways, compounding the nausea that typically accompanies GLP-1 receptor agonist initiation.

Both therapies share the GLP-1 receptor agonist class safety profile: thyroid C-cell tumour risk (boxed warning for MTC/MEN2), potential for hypoglycemia (particularly when combined with insulin or sulfonylureas), gallbladder-related events, and rare pancreatitis risk. Tirzepatide-specific data from T2DM trials show hypoglycemia in 1.7% of patients versus 0.4% with semaglutide. Network meta-analyses have identified Tirzepatide as having the highest risk of discontinuation due to adverse events among anti-obesity medications — a counterintuitive finding given its lower nausea rates, likely reflecting its broader adverse event profile at high doses.

The tolerability trade-off for CagriSema is explicit: the dual gastric emptying delay that enhances satiety and contributes to weight loss also produces higher nausea rates and more challenging dose escalation. Whether this trade-off is clinically acceptable depends substantially on patient phenotype, prior GLP-1 experience, and the degree of weight loss required — considerations that align with precision medicine frameworks advocated by organisations such as the European Medicines Agency.

Therapeutic positioning: matching the right dual incretin strategy to the right patient

The mechanistic differences between CagriSema and Tirzepatide translate into distinct clinical niches rather than a simple hierarchy of efficacy. CagriSema’s profile makes it particularly suitable for patients requiring maximum appetite suppression and prolonged satiety, individuals with prediabetes seeking diabetes prevention (87.7% of prediabetic patients achieved normoglycemia in REDEFINE-2), patients who have plateaued on GLP-1 monotherapy, and those where prevention of weight regain through metabolic adaptation mechanisms is a priority.

Tirzepatide’s positioning favours patients with type 2 diabetes requiring superior glycemic control, individuals with cardiovascular comorbidities (particularly heart failure with preserved ejection fraction), patients prioritising better tolerability and higher likelihood of reaching target doses, those with dyslipidemia (superior triglyceride reduction of 19–24.8% vs. 11.5% for semaglutide), and patients with obstructive sleep apnea and obesity — a condition for which Tirzepatide holds FDA approval as of 2024.

Looking ahead, the competitive landscape for dual and triple incretin strategies is intensifying. Amycretin — a unimolecular GLP-1/amylin dual agonist — combines CagriSema’s receptor targets in a single molecule. Retatrutide adds glucagon-mediated energy expenditure to GIP/GLP-1 dual agonism. Whether triple agonism or refined dual agonism ultimately offers the best benefit-risk profile remains an open research question, with implications for both clinical practice and the drug discovery pipeline that PatSnap’s pharmaceutical intelligence tools are well-positioned to track. The PatSnap research library provides ongoing analysis of these emerging therapeutic categories.